With the goal of identifying potentially druggable interactors with mutant RAS proteins, our group recently identified the novel KRAS–AGO2 interaction (9) and described its role in promoting both pancreatic (11) and NSCLC (12). This evidence concerns the gene KRAS and non-small cell lung carcinoma.